Evidence map›Paper›PMID 41018566›Full record

ArticleACS omega2025

Optimizing Multi-Task Learning with Evolutionary Relatedness Metrics for Enhanced QSAR-Based Natural Product Activity Prediction.

Donny Ramadhan, Reiko Watanabe, Kenji Mizuguchi

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Donny RamadhanGraduate School of Science, The University of Osaka, Toyonaka, Osaka 560-0043, Japan.ORCID https://orcid.org/0000-0001-6556-3160
Reiko WatanabeLaboratory for Computational Biology, Institute for Protein Research, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID https://orcid.org/0000-0001-9359-8731
Kenji MizuguchiGraduate School of Science, The University of Osaka, Toyonaka, Osaka 560-0043, Japan.ORCID https://orcid.org/0000-0003-3021-7078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products exhibit diverse and typically nonflat structures, which could be essential in drug-target interactions. Given limited bioactivity data for natural products in public databases, multitask learning (MTL) offers a promising strategy to improve quantitative structure-activity relationship (QSAR)-based predictions. This study optimized MTL with evolutionary relatedness metrics of proteins to enhance the prediction of natural product bioactivity, particularly when data are scarce, and identified conditions under which MTL is most effective. A curated data set of predicted natural products with bioactivity against enzymes from ChEMBL was constructed using binary classification filtering. Single-task learning (STL) served as the baseline, feature-based MTL (FBMTL) was applied across all proteins within each protein group, and instance-based MTL (IBMTL), a variant of FBMTL, incorporated evolutionary relatedness metrics. IBMTL outperformed STL and FBMTL across most protein groups, suggesting that evolutionary relatedness improves performance. Significant improvements were observed in the kinase and cytochrome P450 protein groups, whose proteins are classified at more specific levels of ChEMBL's 6-level hierarchical protein classification. In the kinase group, IBMTL performed best at the target parent level, highlighting a trade-off between relatedness and data set size. This study demonstrates the potential of MTL in natural product-based drug discovery by leveraging evolutionary relatedness despite limited data availability.

Identifiers

PMID41018566
PMCPMC12461318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.